Why insider trading matters?

If management teams do not own any relevant stakes in the companies they guide, they may not be focused on creating wealth for shareholders to the same degree, compared to those that see their personal wealth increase when share prices rise.

- Klaus Gugler, Economist
ROCKET PHARMACEUTICALS, INC. (RCKT)
Sector: Healthcare; Industry: Biotechnology

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It also has additional infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. In addition, the company has an adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-06-17 Makker Gotham Director Sell 35,085 $46.85 $1,643,693 No
2020-12-28 Patel Kinnari Chief Operating Officer Sell 16,761 $56.72 $950,745 No
2020-12-10 RTW INVESTMENTS, LP 10%-Owner, Director Buy 247,720 $56.00 $13,872,320 No
2020-03-18 Patel Kinnari Chief Operating Officer Buy 1,000 $9.50 $9,500 No
2019-12-10 RTW INVESTMENTS, LP 10%-Owner, Director Buy 225,000 $22.25 $5,006,250 No
2019-04-16 RTW INVESTMENTS, LP 10%-Owner, Director Buy 550,005 $17.50 $9,625,088 No
2019-03-05 Shah Gaurav See Remarks Sell 74,900 $17.17 $1,286,272 No
2018-12-13 SOUTHWELL DAVID P Director Sell 38,768 $15.19 $588,886 No
2018-12-07 SOUTHWELL DAVID P Director Sell 57,732 $15.13 $873,458 Yes
2018-12-06 Patel Kinnari Chief Operating Officer Buy 5,675 $14.98 $85,012 No
2018-08-01 Yalamanchi Naveen Director Sell 637 $22.00 $14,014 No
2017-01-06 SOUTHWELL DAVID P President and CEO Buy 60,000 $1.75 $105,000 No
2016-05-13 CARROLL J MARTIN Director Buy 10,000 $9.03 $90,294 No
2015-02-23 Pitango Venture Capital Principals Fund IV, L.P. 10%-Owner Buy 212,375 $6.00 $1,274,250 Yes
2015-02-23 KARABELAS ARGERIS N 10%-Owner, Director Buy 603,832 $6.00 $3,622,992 Yes
2015-02-23 CARE CAPITAL II LLC 10%-Owner Buy 603,832 $6.00 $3,622,992 Yes
2015-02-23 RHO VENTURES IV QP LP 10%-Owner Buy 958,226 $6.00 $5,749,356 Yes
2015-02-23 Kantesaria Devang 10%-Owner Buy 814,166 $6.00 $4,884,996 Yes
2015-02-23 DEVON PARK BIOVENTURES LP 10%-Owner Buy 814,166 $6.00 $4,884,996 Yes
2015-02-23 MedImmune Ventures, Inc. 10%-Owner Buy 416,667 $6.00 $2,500,002 Yes

Insider Smart

PROSPECT CAPITAL CORP (PSEC) - PSEC is the 2nd most bought stock of the past 90 days by insiders, CEO seems very confident about the company.

Insider Smart

Altimmune, Inc. (ALT) - Venrock Healthcare Capital Partners III, L.P., 10%-owner of ALT bought 1.3M shares in late May then added another 1.5M shares in June with an averaged ~$8 per share. 10 days after the accumulation, ALT price jumped to $10.